PharmD Chiodin - Day One Chief Officer

DAWN Stock  USD 15.01  0.07  0.46%   

Insider

PharmD Chiodin is Chief Officer of Day One Biopharmaceuticals
Address 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
Phone650 484 0899
Webhttps://dayonebio.com

Day One Management Efficiency

The company has return on total asset (ROA) of (0.4222) % which means that it has lost $0.4222 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4571) %, meaning that it created substantial loss on money invested by shareholders. Day One's management efficiency ratios could be used to measure how well Day One manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of October 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.62. At this time, Day One's Net Tangible Assets are very stable compared to the past year. As of the 19th of October 2024, Non Currrent Assets Other is likely to grow to about 263.7 K, while Total Assets are likely to drop about 239.3 M.
Day One Biopharmaceuticals currently holds 408 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Day One Biopharmaceu has a current ratio of 30.82, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Day One's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jannie OosthuizenMerck Company
53
Paul AntebiChevron Corp
47
William CarapezziPfizer Inc
63
Kathleen HoganAlaska Air Group
54
Peter AndronovKBC Groep NV
54
David MoucheronKBC Groep NV
50
Michael McdermottPfizer Inc
55
Dean LiMerck Company
58
Nadja WestJohnson Johnson
60
Mikael GrubbJPMorgan Chase Co
N/A
DVM DVMPfizer Inc
60
Dirk BrinckmanJohnson Johnson
N/A
D DavisJohnson Johnson
69
William HaitJohnson Johnson
71
Jens JensenFrontline
57
D UmplebyChevron Corp
62
Deepak KhannaMerck Company
N/A
A WashingtonJohnson Johnson
70
Elizabeth WindramJetBlue Airways Corp
N/A
Vanessa BroadhurstJohnson Johnson
52
Carol ClementsJetBlue Airways Corp
48
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Day One operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people. Day One Biopharmaceuticals (DAWN) is traded on NASDAQ Exchange in USA. It is located in 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 and employs 169 people. Day One is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Day One Biopharmaceu Leadership Team

Elected by the shareholders, the Day One's board of directors comprises two types of representatives: Day One inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Day. The board's role is to monitor Day One's management team and ensure that shareholders' interests are well served. Day One's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Day One's outside directors are responsible for providing unbiased perspectives on the board's policies.
PharmD Chiodin, Chief Officer
Charles II, CFO COO
Jaa Roberson, Chief Officer
Elly MD, Chief Officer
MBA II, CFO COO
John Stubenrauch, Chief Officer
Adam Dubow, General Counsel
Lauren MBA, Chief Officer
Julie MBA, CoFounder Director
Jeremy MBA, President CEO
Prof MD, Chief Officer
Mike Preigh, Chief Operations

Day Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Day One a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Day One

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.94)
Revenue Per Share
0.095
Return On Assets
(0.42)
Return On Equity
(0.46)
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.